Stocks · News reference
"Looking ahead for the remainder of 2026, we expect our international core growth to moderate as we navigate regional launch dynamics in specific European markets converting to pre-filled syringes. We remain
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-08-14 AccNo: 0001161697-26-000200 Size: 189 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Read original at edgarKORU Medical Systems (NASDAQ:KRMD) narrows FY2026 sales outlook from $47.500 million-$50.000 million to $47.500 million-$48.500 million vs $48.688 million estimate.
Read original at benzingaKORU Medical Systems (NASDAQ:KRMD) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.02) by 200 percent. This is a 100 percent increase over earnings of $0.01 per share from
Read original at benzinga